ImmunoGen, Inc. (IMGN) Financial Statements (2025 and earlier)

Company Profile

Business Address 830 WINTER ST
WALTHAM, MA 02451
State of Incorp. MA
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments571,987201,249275,138309,511373,874437,661
Cash and cash equivalent571,987201,249275,138309,511373,874437,661
Receivables71,50625,66713,8147382,7834,833
Inventory, net of allowances, customer advances and progress billings3,233614    
Inventory3,233614    
Other undisclosed current assets22,54716,33415,16920,16717,26714,224
Total current assets:669,273243,864304,121330,416393,924456,718
Noncurrent Assets
Inventory, Noncurrent17,98116,29116,196   
Operating lease, right-of-use asset8,9979,62710,23110,80911,36111,888
Property, plant and equipment3,7764,0674,3774,4744,3344,431
Other noncurrent assets14,30014,49614,01113,10012,6768,672
Total noncurrent assets:45,05444,48144,81528,38328,37124,991
TOTAL ASSETS:714,327288,345348,936358,799422,295481,709
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities65,46774,95895,24784,55658,79348,198
Employee-related liabilities8,6214,9603,408
Accounts payable18,44132,26045,35320,17817,24516,060
Accrued liabilities47,02642,69849,89455,75736,58828,730
Deferred revenue14,38913,44413,85615,07915,63623,417
Other undisclosed current liabilities13,84613,22712,7554,00712,64212,503
Total current liabilities:93,702101,629121,858103,64287,07184,118
Noncurrent Liabilities
Long-term debt and lease obligation:    12,21713,25414,263
Liabilities, other than long-term debt39,43744,40447,80339,03244,07747,370
Deferred revenue30,21734,05536,35538,73243,61146,694
Other liabilities300300300300466676
Operating lease, liability8,92010,04911,14812,21713,25414,263
Other undisclosed noncurrent liabilities90,34620,39423,44925,90128,06229,490
Total noncurrent liabilities:129,78364,79871,25277,15085,39391,123
Total liabilities:223,485166,427193,110180,792172,464175,241
Equity
Equity, attributable to parent490,842121,918155,826178,007249,831306,468
Common stock2,3742,2612,2602,2082,2062,205
Additional paid in capital2,227,8021,854,7431,847,6381,810,8631,804,9341,799,551
Accumulated deficit(1,739,334)(1,735,086)(1,694,072)(1,635,064)(1,557,309)(1,495,288)
Total equity:490,842121,918155,826178,007249,831306,468
TOTAL LIABILITIES AND EQUITY:714,327288,345348,936358,799422,295481,709

Income Statement (P&L) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Revenues83,15349,86941,16715,37514,16238,078
Gross profit:83,15349,86941,16715,37514,16238,078
Operating expenses(87,342)(92,262)(100,726)(92,804)(75,215)(60,930)
Operating income (loss):(4,189)(42,393)(59,559)(77,429)(61,053)(22,852)
Nonoperating income (expense)5,2152,2322,740541110(44)
Investment income, nonoperating5,2232,1692,1581,53959054
Other nonoperating income (expense)(8)63582(998)(480)(98)
Interest and debt expense      
Income (loss) from continuing operations before equity method investments, income taxes:1,026(40,161)(56,819)(76,888)(60,943)(22,896)
Other undisclosed loss from continuing operations before income taxes(4,397) (4,165)   
Income (loss) from continuing operations before income taxes:(3,371)(40,161)(60,984)(76,888)(60,943)(22,896)
Income tax expense (benefit)(877)     
Other undisclosed loss from continuing operations   (1,218)   
Income (loss) from continuing operations:(4,248)(40,161)(62,202)(76,888)(60,943)(22,896)
Loss before gain (loss) on sale of properties:(76,888)(60,943)(22,896)
Other undisclosed net income (loss)  (853)3,194  (1,249)
Net income (loss):(4,248)(41,014)(59,008)(76,888)(60,943)(24,145)
Other undisclosed net loss attributable to parent    (867)(1,078) 
Net income (loss) attributable to parent:(4,248)(41,014)(59,008)(77,755)(62,021)(24,145)
Other undisclosed net loss available to common stockholders, basic      
Net income (loss) available to common stockholders, diluted:(4,248)(41,014)(59,008)(77,755)(62,021)(24,145)

Comprehensive Income ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net income (loss):(4,248)(41,014)(59,008)(76,888)(60,943)(24,145)
Comprehensive income (loss):(4,248)(41,014)(59,008)(76,888)(60,943)(24,145)
Other undisclosed comprehensive loss, net of tax, attributable to parent    (867)(1,078) 
Comprehensive income (loss), net of tax, attributable to parent:(4,248)(41,014)(59,008)(77,755)(62,021)(24,145)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: